HKPDNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31

Cellyan Biotechnology Co., Ltd

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Aug 7, 2026

$0.11+0.00 (+1.81%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Cellyan Biotechnology Co., Ltd income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31
Revenue	13	20	17	13
Cost of Revenue	12	18	13	9.82
Gross Profit	1.39	2.42	3.56	2.74
Selling, General & Admin	2.40	2.22	1.89	1.76
Operating Income	-2.39	-2.28	-1.95	-1.79
Interest Expense	0.13	0.10	0.08	0.02
Interest & Investment Income	0.00	0.00	0.00	0.00
Pretax Income	-1.13	0.04	1.53	1.02
Income Tax Expense	0.01	0.06	0.20	0.02
Net Income incl. Noncontrolling Interests	-1.14	-0.03	1.33	1.00
Net Income	-1.14	-0.03	1.33	1.00
Net Income to Common	-1.14	-0.03	1.33	1.00
EPS (Basic)(per share)	-0.07	-0.0030	0.18	0.15
EPS (Diluted)(per share)	-0.07	-0.0030	0.18	0.15
Shares Outstanding (Basic, Weighted)(shares)	16	10	7.37	6.84
Shares Outstanding (Diluted, Weighted)(shares)	16	10	7.37	6.84
EBITDA	-2.30	-2.21	-1.89	-1.72

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY2026

Gross margin: 10.3%
Operating margin: -17.8%
Net margin: -8.5%
Return on equity, FY2026: -15.5%

Financial strength

Current ratio: 3.86
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 6.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –